The Cooper Cos. (NYSE:COO) shares hit a new 52-week high during trading on Friday . The company traded as high as $183.86 and last traded at $182.67, with a volume of 51,301 shares trading hands. The stock had previously closed at $181.77.

A number of analysts have recently weighed in on COO shares. Robert W. Baird reissued an “outperform” rating and set a $185.00 price objective on shares of The Cooper Cos. in a research note on Saturday, June 25th. Cleveland Research raised The Cooper Cos. from a “neutral” rating to a “buy” rating in a research note on Monday, May 16th. Piper Jaffray Cos. reissued an “overweight” rating and set a $185.00 price objective on shares of The Cooper Cos. in a research note on Tuesday, July 26th. Jefferies Group raised The Cooper Cos. from a “hold” rating to a “buy” rating and set a $175.00 price objective for the company in a research note on Friday, April 15th. Finally, Stifel Nicolaus increased their price objective on The Cooper Cos. from $180.00 to $195.00 and gave the company a “buy” rating in a research note on Thursday, June 30th. Four analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The Cooper Cos. presently has an average rating of “Buy” and an average price target of $167.00.

The stock has a 50-day moving average price of $175.65 and a 200-day moving average price of $156.23. The stock has a market capitalization of $8.86 billion and a price-to-earnings ratio of 43.26.

The Cooper Cos. (NYSE:COO) last released its quarterly earnings data on Thursday, June 2nd. The medical device company reported $2.05 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.91 by $0.14. During the same quarter last year, the firm posted $1.72 earnings per share. The firm earned $484.80 million during the quarter. The Cooper Cos.’s revenue was up 11.5% on a year-over-year basis. Analysts forecast that The Cooper Cos. will post $8.40 EPS for the current year.

The business also recently announced a semiannual dividend, which was paid on Friday, August 5th. Stockholders of record on Friday, July 22nd were given a dividend of $0.03 per share. This represents a dividend yield of 0.03%. The ex-dividend date of this dividend was Wednesday, July 20th.

In other news, Director A Thomas Bender sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, June 13th. The stock was sold at an average price of $163.51, for a total transaction of $327,020.00. Following the transaction, the director now owns 14,978 shares of the company’s stock, valued at approximately $2,449,052.78. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Michael Kalkstein sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, July 8th. The shares were sold at an average price of $178.55, for a total value of $178,550.00. Following the transaction, the director now directly owns 14,215 shares in the company, valued at approximately $2,538,088.25. The disclosure for this sale can be found here.

Several institutional investors recently added to or reduced their stakes in the stock. Gulf International Bank UK Ltd increased its position in The Cooper Cos. by 3.6% in the fourth quarter. Gulf International Bank UK Ltd now owns 14,531 shares of the medical device company’s stock valued at $1,950,000 after buying an additional 500 shares in the last quarter. Andra AP fonden increased its position in The Cooper Cos. by 8.8% in the fourth quarter. Andra AP fonden now owns 9,900 shares of the medical device company’s stock valued at $1,329,000 after buying an additional 800 shares in the last quarter. Principal Financial Group Inc. increased its position in The Cooper Cos. by 2.7% in the fourth quarter. Principal Financial Group Inc. now owns 154,051 shares of the medical device company’s stock valued at $20,674,000 after buying an additional 4,043 shares in the last quarter. I.G. Investment Management LTD. increased its position in The Cooper Cos. by 40.6% in the fourth quarter. I.G. Investment Management LTD. now owns 30,760 shares of the medical device company’s stock valued at $4,128,000 after buying an additional 8,884 shares in the last quarter. Finally, Mizuho Trust & Banking Co. Ltd. increased its position in The Cooper Cos. by 13.5% in the fourth quarter. Mizuho Trust & Banking Co. Ltd. now owns 79,274 shares of the medical device company’s stock valued at $10,740,000 after buying an additional 9,454 shares in the last quarter.

The Cooper Companies, Inc (Cooper) is a medical device company. The Company operates through two business units: CooperVision, Inc (CooperVision) and CooperSurgical, Inc (CooperSurgical). CooperVision develops, manufactures and markets a range of soft contact lenses for the vision correction market. CooperVision offers Biofinity monthly spherical, toric and multifocal lenses under the Avaira brand.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.